Detection of Hypermethylated Vimentin in Urine of Patients with Colorectal Cancer  by Song, Benjamin P. et al.
The Journal of Molecular Diagnostics, Vol. 14, No. 2, March 2012
Copyright © 2012 American Society for Investigative Pathology
and the Association for Molecular Pathology.
Published by Elsevier Inc. All rights reserved.
DOI: 10.1016/j.jmoldx.2011.12.003Technical Advance
Detection of Hypermethylated Vimentin in Urine of
Patients with Colorectal CancerBenjamin P. Song,* Surbhi Jain,* Selena Y. Lin,*
Quan Chen,* Timothy M. Block,* Wei Song,†
Dean E. Brenner,‡ and Ying-Hsiu Su*
From the Department of Microbiology and Immunology,* Drexel
University College of Medicine, Philadelphia, Pennsylvania; JBS
Science Inc,† Doylestown, Pennsylvania; and the Departments of
Internal Medicine and Pharmacology,‡ University of Michigan
Medical Center, Ann Arbor, Michigan
We demonstrated previously that urine contains low-
molecular-weight (LMW) (<300 bp), circulation-derived
DNA that can be used to detect cancer-specificmutations
if a tumor is present. The goal of this study was to
develop an assay to detect the colorectal cancer (CRC)–
associated, circulation-derived, epigenetic DNA marker
hypermethylated vimentin gene (mVIM) in the urine of
patients with CRC. An artificial 18-nucleotide DNA se-
quence was tagged at the 5= end of the primers of the
first PCR cycle to increase the amplicon size, which
was then integrated into the primers of the second
PCR cycle. A quantitative MethyLight PCR-based as-
say targeting a 39-nucleotide template was devel-
oped and used to quantify mVIM in CRC tissues and
matched urine samples. mVIM was detected in 75%
of LMW urine DNA samples from patients with CRC
(n  20) and in 10% of urine samples of control
subjects with no known neoplasia (n  20); 12 of 17
LMW urine DNA samples (71%) but only 2 of 17
high-molecular-weight urine DNA samples (12%)
from patients with mVIM-positive tissues contained
detectable mVIM, suggesting that the mVIM detected
in LMW urine DNA is derived from the circulation. The
detection of mVIM in urine was significantly associated
with CRC compared with controls (P < 0.0001, by Fish-
er’s exact test). A potential urine test for CRC screening
using epigenetic markers is discussed. (J Mol Diagn
2012, 14:112-119; DOI: 10.1016/j.jmoldx.2011.12.003)
Colorectal cancer (CRC) remains the second leading
cause of cancer deaths in the United States (49,380
projected deaths in 2011)1 despite the availability of sen-
112sitive screening tests, such as colonoscopy. The incon-
venience of the test and the risks involved contribute to
the low adherence rate (40%) in US adults. The noninva-
sive fecal occult blood test is also available, but its sen-
sitivity is low (30%). Fecal DNA tests for CRC screening
have been extensively studied and gave encouraging
results (up to 90% sensitivity) with open-labeled study
participants.2–6 However, the sensitivity to detect CRC
fell to 52% in large multicenter validation studies in an
average-risk population7,8 and as reviewed by Bonanno
et al9 and Levin et al.10 This result could be due to the
massive contamination from bacterial DNA in stool.11,12
Thus, early detection of colon cancer by currently avail-
able screening methods remains a major challenge.
Circulating DNA has been studied for decades for
cancer detection, including detection of CRC.12–22 How-
ever, it has not proved to be sufficiently sensitive to de-
tect tumor-associated DNA alterations in the circulation.
We and others have shown that urine contains DNA from
the circulation15,23–29 and that circulation-derived DNA in
urine is fragmented into segments of 300 bp [low-mo-
lecular-weight (LMW) urine DNA] that can be used to
detect cancer-derived genetic mutations if the tumor is
present. We have also shown that preferentially isolating
LMW urine DNA from total urine DNA to use as the sub-
strate enhanced the sensitivity and specificity of the test
for detecting tumor-derived circulating K-ras–mutated
DNA marker.30 Thus, we suggest that LMW DNA in urine
could be used as a substrate for detecting circulation-
derived DNA markers. However, because tumor-derived
circulating DNA in urine is fragmented,24,31 several re-
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targeting a small template size is required to have suffi-
cient sensitivity to detect the DNA of interest.12,32–36
Aberrant hypermethylation of tumor suppressor genes
occurs early and throughout the process of colorectal
carcinogenesis.5,37–43 These DNA alterations could be
used as biomarkers for cancer detection and disease
management.37,43,44 Among the epigenetic DNA mark-
ers, the aberrant hypermethylated vimentin gene
(mVIM) has shown great promise in fecal DNA tests for
CRC screening8,37–39,45–47 and was detected in the
serum of patients with CRC.20 Detection of methylated
DNA markers has been challenging when the source of
substrate DNA was fragmented or in low quantity, such
as DNA isolated from formalin-fixed, paraffin-embed-
ded sections, because the process of bisulfite (BS)
conversion further fragments the DNA,48,49 and it was
suggested that approximately 99.9% of the DNA was
lost in this process.48 To detect circulation-derived
mVIM in the urine of patients with CRC in this study, we
developed an assay targeting a 39-nucleotide (nt) seg-
ment of the hypermethylated region in the vimentin
gene that was associated with CRC. Using LMW urine
DNA as the substrate and the short amplicon assay
that we developed, we demonstrated that the circula-
tion-derived, CRC-associated methylated DNA marker
mVIM can be detected in the urine of patients with
CRC. The potential of this assay for developing a urine
Table 1. Clinical Profiles of Patients with CRC and No-Known-N
ID
CRC
Urine
sample ID
Tissue
sample ID TNM Stage
A U20 T15 2/0/? I
B U19 T13 2/1/? IIIa
C U12 T14 3/1/?
D U11 T17 3/1/X IIIb
E U1 T5 3/1/1 IV
F U5 T12 3/0/X IIa
G U18 T18 1/0/0 I
H U3 T8 4/0/1 IV
I U14 T20 3/2/X IIIc
J U16 T10 2/0/X Ic
K U8 T9 3/0/X IIa
L U10 T2 3/2/1 IV
M U9 T16 3/0/X IIa
N U15 T4 4/0/0 IIb
O U17 T6 4/2/1 IV
P U13 T19 3/0/X IIa
Q U7 T11 1/0/X I
R U4 T3 3/0/0 IIa
S U6 T7 3/2/0 IIIc
T U2 T1 3/0/X IIa
Age, mean (years)
(P  0.00048†)
60.45
Sex, F/M (No.)
(P  0.11‡)
6/14
*Controls with no known neoplasia were enrolled from endoscopy sui
†By Student’s t-test.
‡By Fisher’s exact test.
F, female; M, male; TNM, tumor node metastasis.test to detect CRC is discussed.Materials and Methods
Study Participants and Specimens
Participants were recruited from the Great Lakes–New
England Clinical Epidemiology and Validation Center
(Ann Arbor, MI) under institutional review board approval.
Patients with cancer were enrolled from surgical or on-
cologic services before treatment, and controls with “no
known neoplasia” were enrolled from endoscopy suites,
where they had undergone colonoscopies that yielded
negative results. All the participants gave informed con-
sent. The clinical profiles of patients with CRC and no-
known-neoplasia controls are summarized in Table 1.
Urine Collection, DNA Isolation, and
Fractionation of LMW and High-Molecular-
Weight DNA
A total of 0.5 mol/L EDTA, pH 8.0, was added to freshly
collected urine to a final concentration of 10 mmol/L
EDTA to inhibit possible nuclease activity; the mixture
was stored at 70°C. To isolate total urine DNA, the
frozen urine sample was thawed at room temperature
and then placed immediately in ice before the DNA was
isolated. Total urine DNA was isolated from the thawed
urine within an hour as described previously.24 The LMW
urine DNA and high-molecular-weight (HMW) urine DNA
fractions were obtained using carboxylated magnetic
a Controls
No known neoplasia*
Age
(years) Sex
Urine
sample ID
Age
(years) Sex
63 M N1 75 F
69 M N2 63 F
58 M N3 71 F
79 F N4 78 M
54 M N5 72 M
75 F N6 79 M
80 M N7 79 F
45 M N8 85 M
69 M N9 82 F
69 M N10 68 F
36 M N11 66 M
64 M N12 69 F
65 F N13 77 F
32 M N14 65 F
59 F N15 67 F
74 M N16 82 M
46 F N17 69 F
46 M N18 88 M
67 F N19 62 M
59 M N20 79 F
73.8
12/8
ere they had undergone colonoscopies that yielded negative results.eoplasi
tes, whbeads (Agencourt Bioscience Corp., Beverly, MA) and a
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(Philadelphia, PA).30 DNA from paraffin-embedded tis-
sue sections was isolated using the MasterPure DNA kit
(Epicentre Biotechnologies, Madison, WI) per the manu-
facturer’s instructions.
BS Treatment
BS conversion of DNA was performed using EpiTect
BS conversion kits (Qiagen Inc, Valencia, CA) accord-
ing to the manufacturer’s specifications. To evaluate
the efficiency of the BS conversion, BS-converted DNA
was subjected to PCR amplification using BS-specific
primer sets, as described previously.14 The PCR prod-
uct was analyzed and visualized by gel containing
ethidium bromide, excised, and purified by the Qiagen
gel extraction kit (Qiagen Inc.); it was then sent to
NapCore (Children’s Hospital of Philadelphia, Philadel-
phia, PA) for DNA sequencing. The DNA sequencing
data were compared with the sequence generated by
the Methyl Primer Express software (Applied Biosys-
tems, Foster City, CA) using ClustalW software (Euro-
pean Bioinformatics Institute, Cambridge, UK). The ef-
ficiency of the BS conversion was determined as the
percentage of the number of non-CpG cytosine mole-
cules that became thymidine compared with the per-
centage of the total number of non-CpG cytosine mol-
ecules in the region. Only samples that were converted
with an efficiency of 95% were analyzed.
DNA Quantification by Real-Time PCR
DNA was quantified by a real-time PCR amplifying
globin DNA as previously described.50 To quantify the
BS-converted DNA, we developed a real-time PCR
assay, BS-actin, targeting the BS-converted actin gene
sequences. The primers, listed in Table 2, were de-
signed within the regions that did not have any CpG
sites in the gene so that the status of CpG methylation
would not affect the primer binding. The BS-actin PCR
was performed using the LightCycler 480 real-time
PCR system (Roche Biochemical, Mannheim, Germany)
and the LightCycler 480 SYBR Green I master kit
(Roche Biochemical). The reaction contained 1 SYBR
Green master mix, 1.0 mol/L primers, and the BS-
Table 2. Oligonucleotides Used in the Study
Assay (Genbank) Olig
BS-actin (NT_007819) Forward: 5=-GATGTA
Reverse: 5=-CTAACT
MSP2945 (AL133415) MSP29F: 5=-TCGTTT
MSP29R: 5=-CGACT
VIM29R_LNA 2-step MethyLight 1F: 5=-GCTCTTCGTG
1R: 5=-GCTCTTCGTG
2F: 5=-GTGTGGTGCG
2R: 5=-GTGTGGTGCT
TaqMan probe: FAM*The artificial DNA sequences are underlined, and LNAs are in bold.converted DNA template. The PCR was performed un-
der the following conditions: 95°C for 10 minutes to
activate the Taq polymerase, then 95°C for 10 sec-
onds, 55°C for 20 seconds, 72°C for 10 seconds for 45
cycles, followed by determination of the melting curve
at 95°C for 5 seconds, 65°C for 1 minute, and 97°C for
continuous hold. Cooling occurred at 40°C for 30 sec-
onds. The linearity and sensitivity of the assay were
determined by performing the assay using a 10-fold
dilution of the BS-converted human universal methyl-
ated DNA control (Zymo Research, Irvine, CA) (see
Supplemental Figure S1 at http://jmd.amjpathol.org).
Development of PCR Assays for the Aberrant
Methylation of the Vimentin Gene
To develop the MethyLight assay for mVIM, target se-
quences from the promoter and first exon regions of the
vimentin gene were obtained from GenBank (AL133415)
using PubMed software (National Center for Biotechnol-
ogy Information, Bethesda, MD). CpG analysis was per-
formed using Methyl Primer Express software (Applied
Biosystems). Primers and probes for a two-step nested
MethyLight assay targeting template sizes of 39 nt were
designed (Table 2). The first PCR was performed in a
thermocycler (Eppendorf, Hamburg, Germany) using the
first PCR primer set (0.1 mol/L), dNTP (20 mol/L), and
HotStar Taq (Qiagen Inc.) under the following conditions:
95°C for 15 minutes to activate the HotStar Taq polymer-
ase, then 95°C for 30 seconds, 62°C for 30 seconds,
72°C for 20 seconds for 30 cycles, and 72°C for 5 min-
utes. The second PCR was performed using the Light-
Cycler 2.0 PCR instrument with the second PCR primers
(0.5 mol/L each) and TaqMan probe (0.15 mol/L), 1 L
of first PCR product (1:20 dilution) with Roche LightCycler
TaqMan 5x master mix under the following conditions:
95°C for 10 minutes and 40 cycles at 95°C for 10 sec-
onds, 60°C for 10 seconds, and 72°C for 10 seconds;
cooling occurred at 40°C for 30 seconds.
To determine the linearity and sensitivity of the assay,
reconstituted standard samples ranging from 5 to 500
copies of a series of BS-converted universal methylated
human DNA standard (Zymo Research), with a negative
control, 100 copies of BS-treated human unmethylated
DNA standard (Zymo Research) were used to assess
otide sequences*
Annealing
temperature (°C)
GTTTTTGG-3= 55
CACCCACTC-3=
TTTTCGCGTTAGAGAC-3= 68
TCGACCGACTCGCGA-3=
GTGCGGTTCGGGTATCGC-3= First PCR: 62
GTGCTCCGACTAAAACTCGACC-3=
3= Second PCR: 60
-3=
CGAGTCGGTCGAGTT-BHQ1onucle
TGAAG
ACCTC
CGAGG
AAAAC
GTGTG
GTGTG
GTTC-
CCGAC
-ATCG
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specific PCR assay for the mVIM, the MSP29 assay,37
was used as a control assay to evaluate the methylation
status of the vimentin gene in CRC tissue.
Results
Development of a MethyLight Assay to Detect
the mVim Gene in Fragmented Short DNA
Templates
It has been suggested that PCR assays that target tem-
plate sequences of 50 nt are necessary to obtain a
sensitivity 50% to detect DNA of interest in urine de-
rived from the circulation.34,35 To develop an assay for
detecting mVIM in circulation-derived urine DNA, we first
identified a target region, the MSP29R region (Figure 1A),
57800 58206
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Figure 1. Development of a two-step MethyLight PCR assay for the mVIM
gene. A: Schematic location of the CpG sites generated by the Methyl
Primer Express software in the promoter and the first exon regions of the
vimentin gene (GenBank AL133415) and the locations of the forward and
reverse primer regions of the MSP29 methylation-specific PCR assay37 are
indicated. Each vertical line represents a CpG site. B: Schematic diagrams
of the two-step nested quantitative MethyLight assay. The green line
represents the target sequence. For the two-step PCR assay, the forward
and reverse primers of the first PCR cycle include the targeted sequence
and an artificial sequence (orange). The second PCR cycle has a forward
and a reverse primer (with mostly artificial sequences shown in orange)
and a TaqMan probe. C: Amplification curves of the mVIM MethyLight
assay VIM29R_LNA. The amplification curves and the linear standard were
generated from a reconstituted standard as described in Materials and
Methods. The numbers of copies of positive control DNA, negative control
DNA (Neg), and H2O are indicated.for assay development. The MSP29R region was chosen
because of the results of a comprehensive study by Chen
et al45 that analyzed the promoter and first exon regions
of the vimentin gene. The results indicated that the region
studied using the methylation-specific PCR assay MSP29
had the highest specificity and sensitivity as a biomarker
for CRC; the specificity of using the MSP29 assay for
detecting mVIM in CRC was confirmed by other investi-
gators.39,46,47 Because the primer sequences determine
the specificity of the PCR assay, the reverse primer re-
gion of MSP29 (designated MSP29R; Figure 1) was cho-
sen for assay design.
Two strategies were applied to shorten the target
size and enhance assay sensitivity, as illustrated in
Figure 1, A and B; the primer sequences are listed in
Table 2. First, an artificial 18-nt DNA sequence, 5=-
GCTCTTCGTGGTGTGGTG-3=, was tagged at the 5=
end of the first PCR primers to increase the amplicon
size, and then it was used as part of the primer se-
quences for the second PCR (Table 2). Second, two
locked nucleic acids (LNAs) were incorporated into the
reverse primer of the first PCR assay at two CpG sites
to allow for more sensitive priming of the assay. Ac-
cordingly, a two-step MethyLight assay targeting a
template of 39 nt, designated VIM29R_LNA, produced
a specific PCR product from the positive control tem-
plates (100 copies of BS-actin–quantified, BS-con-
verted WiDr DNA) and no product from the negative
control templates (500 copies of BS-actin–quantified,
BS-converted HepG2 DNA) (data not shown). The am-
plification curve and linearity of the VIM29R_LNA assay
are shown in Figure 1C. This assay can detect 5
copies of mVIM per reaction quantitatively in the pres-
ence of 500 copies of BS-converted HepG2 DNA (neg-
ative control).
Detection of mVIM in Colorectal Tumor and
Matched Urine Samples in a Blinded Study
We evaluated whether the developed assay,
VIM29R_LNA, could detect mVIM in the urine of patients
with CRC. A blinded study was performed using match-
ing tissue and urine DNA samples from patients with
CRC. The 20 CRC tissue samples and 20 urine samples
from patients with CRC were provided with barcodes; the
researchers did not know which tissue sample matched
which urine sample. Total urine DNA was isolated, frac-
tionated into LMW and HMW DNA, subjected to BS con-
version, and quantified by the BS-actin real-time PCR
assay, as described in Materials and Methods. We first
assessed the variability of the VIM29R_LNA assay in clin-
ical urine samples. Each urine DNA sample was tested in
triplicate. DNA, equivalent to 1 mL of urine, was sub-
jected to each assay. Since no detectable amplification
signal was generated with 500 copies of BS-converted
HepG2 DNA (negative control), we valued any positive
data generated even if it represented 5 copies, the
lowest standard that was used in the assay. The mean 
SEM values for mVIM were calculated for each sample
(Table 3). The percentage of the SE for all the triplicate
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JMD March 2012, Vol. 14, No. 2data sets except two (U2 and U8) was less than 10%,
showing high reproducibility. Encouragingly, 75% (15 of
20) of the LMW urine DNA from patients with CRC con-
tained detectable mVIM. In contrast, only two HMW urine
DNA fractions, U2 and U11, contained detectable
amounts of mVIM (Table 4). As expected, the LMW urine
DNA fractions of U2 and U11 were positive for mVIM.
It was of interest to see whether a previously estab-
lished mVIM assay, MSP29, which amplified a 216-nt
segment of template,45 could detect mVIM in LMW urine
Table 3. Variability of the VIM29R_LNA Assay for Detecting mVI
Sample ID
Meth
Experiment 1 Experi
U1 47 43
U2 348.95 965
U3 3.85 2
U4 27.95 29
U5 6.5 7
U6 13.7 9
U7 ND N
U8 291 450
U9 ND N
U10 400.45 406
U11 3.7 N
U12 93.6 91
U13 ND N
U14 2.65 1
U15 ND N
U16 ND 6
U17 ND N
U18 58.2 74
U19 46.4 40
U20 4.1 4
NA, not applicable; ND, not detectable.
Table 4. Detection of mVIM in LMW Urine DNA Isolated from th
VIM29R_LNA Assay
CRC
Sample
ID
LMW (copies/mL)*
VIM29R_LNA MSP29 BS-actin VIM
U1 38.88 ND 267.3
U2 511.7 ND 149.5
U3 3.75 ND 174.5
U4 28.95 ND 256.3
U5 6.85 ND 673.8
U6 11.8 ND 59.7
U7 ND ND 239.3
U8 386.7 ND 628.2
U9 ND ND 477.9
U10 400.35 ND 79.1
U11 3.23 ND 51.8
U12 89.4 ND 222.2
U13 ND ND 57.4
U14 2.18 ND 97.3
U15 ND ND 68.6
U16 4.95 ND 264.4
U17 ND ND 173.7
U18 64.3 ND 16.4
U19 42.8 ND 135.8
U20 4.35 ND 926.7*The quantity of DNA presented is the average of two or three independent a
ND, not detectable.DNA fractions from patients with CRC. None of the
LMW urine DNA fractions were positive for mVIM by the
MSP29 assay. As controls, 20 LMW urine DNA fractions
from the no-known-neoplasia group were also sub-
jected to the VIM29_LNA assay. Two of 20 LMW urine
DNA fractions had a low amount of mVIM (Table 4). As
a control for the amount of input DNA templates in
mVIM-negative DNA samples, the amount of BS-con-
verted -actin templates in each DNA sample deter-
mined by the BS-actin PCR assay was also listed.
rine DNA
VIM29R (copies/mL of urine)
Experiment 3 Mean  SEM
34 38.88  6.89
220.6 511.68  398.22
4.6 3.75  0.90
29.4 28.95  0.87
6.35 6.85  0.74
12.45 11.8  2.30
ND NA
419.15 386.7  84.3
ND NA
394.45 400.4  5.85
2.75 3.23  0.67
82.9 89.4  5.71
ND NA
ND 2.18  0.67
ND NA
3.9 4.95  1.48
ND NA
60.5 64.3  8.7
41.4 42.67  3.29
4.2 4.35  0.35
e of Patients with CRC and No-Known-Neoplasia Controls by the
No known neoplasia
copies/mL)*
Sample
ID
LMW (copies/mL)*
A BS-actin VIM29R_LNA BS-actin
36.3 N1 ND 83.6
5.8 N2 60 294
210 N3 ND 38.8
33.9 N4 ND 1148
979 N5 9.4 80.4
19.8 N6 ND 43.6
190 N7 ND 33.2
234 N8 ND 123.6
150 N9 ND 32.8
15 N10 ND 97.2
10.3 N11 ND 237.6
31 N12 ND 784
42.6 N13 ND 20.4
117.2 N14 ND 82.8
101.3 N15 ND 148.8
149.7 N16 ND 46.4
817 N17 ND 35.6
11.2 N18 ND 26.6
258 N19 ND 16.4
152 N20 ND 30M in U
ylated
ment 2
.75
.5
.8
.5
.7
.25
D
D
.15
D
.7
D
.7
D
D
.3
.2
.75e Urin
HMW (
29R_LN
ND
4.6
ND
ND
ND
ND
ND
ND
ND
ND
4.5
ND
ND
ND
ND
ND
ND
ND
ND
NDssays.
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associated with CRC [15 of 20; 95% confidence inter-
val (CI), 10.55–17.83[ compared with the no-known-
neoplasia controls (2 of 20; 95% CI, 0.31–6.264) (P 
0.0001 by Fisher’s exact test).
Next, a blinded study was performed by determining
the amount of mVIM in CRC tissue and urine DNA. We
subjected 5 ng of CRC tissue DNA to the VIM29R_LNA
assay in triplicate; the averages are given in Table 5.
mVIM was detectable in 85% (17 of 20) of the CRC tissue
DNA samples, although some of the samples contained a
low level of mVIM. After all the samples were tested, the
urine and tissue ID numbers were unblinded and
matched as listed in Table 5. Although this was a pilot
study to determine whether the VIM29R_LNA assay could
detect circulation-derived mVIM, it was of interest to see
whether there was any correlation between the mVIM-
positive CRC tissue and matched urine DNA samples
and whether the amount of mVIM detected in urine could
be correlated with the stage of the cancer. We, therefore,
generated a two-way contingency table (Table 6) and
found no significant association between the detection of
mVIM in urine and in matched CRC tissue (P 0.5395, by
Fisher’s exact test). To compare the amount of mVIM
detected in urine with the stages of CRC, we divided the
CRC samples in two groups (stages I and II and stages III
and IV) and calculated the average amount of mVIM
detected in the urine samples of each group. The aver-
age amount of mVIM was 91.73 copies/mL of urine for
stages I and II and 63.2 copies/mL of urine for stages III
and IV. The P value was 0.700 by Student’s t-test, sug-
gesting that the amount of mVIM detected in urine is not
Table 5. Detection of mVIM in Tissue and Corresponding Urine
DNA Samples
Patient ID
Matched
samples, after
unblinding
Methylated VIM29R
copies*
Tissue Urine
A T15/U20 0.9 4.4
B T13/U19 1.8 42.8
C T14/U12 2 89.4
D T17/U11 2.1 3.3
E T5/U1 5 41.6
F T12/U5 33.5 6.9
G T18/U18 145 64.4
H T8/U3 235 3.5
I T20/U14 430 2.2
J T10/U16 990 5.9
K T9/U8 1975 386.7
L T2/U10 3150 400.4
M T16/U9 19 ND
N T4/U15 24.5 ND
O T6/U17 60 ND
P T19/U13 460 ND
Q T11/U7 4305 ND
R T3/U4 ND 29.0
S T7/U6 ND 11.8
T T1/U2 ND 511.7
Incidence [No./total No. (%)] 17/20 (85) 15/20 (75)
*Values are given as means (n  3).
ND, not detectable.correlated with the stage of CRC.Discussion
We detected, for the first time, a CRC-associated epige-
netic hypermethylation DNA marker in the urine of pa-
tients with CRC using a two-step MethyLight PCR assay
targeting a 39-nt sequence of mVIM that was developed
in this study. In addition to genetic mutation markers,
epigenetic methylated DNA markers could potentially be
included in a urine test for the detection of CRC.
This project emphasizes the importance of having an
assay that can detect small templates if the substrates are
short fragments. The VIM29R_LNA assay, which targets the
39-nt template, detected mVIM in 75% of LMW urine DNA
fractions, whereas the MSP29 assay, which also detected 5
copies ofmVIM per reaction (data not shown), targeting the
216-nt template, did not detect mVIM in any of the LMW
urine DNA fractions. This difference cannot be attributed to
the difference in the region assayed because the
VIM29R_LNA assay targets the reverse primer of MSP29;
80% of the matched CRC tissues were positive for mVIM,
which is similar to the incidence ofmVIM in CRC in previous
studies using the MSP29 assay.45
Although we detected mVIM in 75% of the LMW urine
DNA samples (n  12) from patients with CRC, only two
of those corresponding HMW urine DNA fractions con-
tained detectable amounts of mVIM. As suggested from
previous studies,24,30 the HMW urine DNA was derived
mostly from sloughed off cell debris from the urinary tract.
The circulation-derived DNA was found primarily in the
LMW urine DNA fraction. The present data further confirm
that urine contains DNA from the circulation and that
circulation-derived urine DNA is mostly in the LMW urine
DNA fraction. Moreover, we demonstrated that the mVIM
detected in the urine of patients with CRC was derived
from the circulation, probably from CRC tissue. Ten per-
cent of urine samples from the no-known-neoplasia con-
trols were positive for mVIM in urine. This finding is not
surprising because the methylation of mVIM was found in
approximately 10% to 15% of normal colon tissue sam-
ples.39,45,46 It is also possible that the 10% of mVIM in
urine samples was from tissue other than colon tissue.
LNA molecules have been successfully used by
us50–52 and others53–59 to increase PCR assay sensitivity.
By incorporating LNAs into the reverse primer of the first
PCR reaction, we successfully increased 10-fold the sen-
sitivity of the two-step PCR assay for detecting mVIM
(data not shown). In the process of assay development,
we also tested the forward and reverse primers that con-
tained LNAs at the CpG sites for the first PCR reaction.
Table 6. Two-Way Contingency Table of Detection of mVIM in
Tissue versus Urine
Tissue mVIM
Urine mVIM
Total 
 12 5 17
 3 0 3
Total 15 5 20Table entries are number of participants; Fisher’s exact t-test, P 
0.5395.
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specificity of the assay decreased with nonspecific prim-
ing during the PCR (data not shown). Although we used
various combinations of LNA and regular DNA-only prim-
ers, the only combination that demonstrated a 10-fold
increase in sensitivity and generated only one expected
PCR product was that of the regular DNA-only forward
primer and the LNA-containing reverse primer in the first
PCR reaction. This observation could be due to the na-
ture of the LNA, which has a high binding affinity, thus
increasing the opportunity for intermolecular interaction.
The detection of mVIM in CRC tissues (Table 4) is
consistent with the results of previous studies in which
mVIM was found in 70% to 80% of CRC tissue sam-
ples.39,45–47 In this pilot study, with a sample size of 20,
we also detected a similar proportion (75%) of urine sam-
ples containing mVIM from patients with CRC. Although
the detection of mVIM in urine is significantly associated
with CRC compared with no known neoplasia (P 
0.0001 by Fisher’s exact test), the amount of mVIM de-
tected in urine was not correlated with the stages of CRC
(P  0.700 by Student’s t-test) when comparing the aver-
age of mVIM in stages I and II (91.73 copies/mL of urine)
versus stages III and IV (63.2 copies/mL of urine). The
two-way contingency table analysis (Table 6) suggests that
the concordance between detection ofmVIM in urine and in
its matched CRC tissue is not significant (P  0.5395),
probably because the sample size is too small.
In patients R, S, and T, mVIM was not detected in CRC
tissue samples but was detected in the corresponding
urine samples (Table 5). This difference may be due to
the fact that the DNA extracted from the tissue samples
had no mVIM, whereas the DNA from other sites in the
body had mVIM that was detected in the urine assay.
However, some tissue samples had large amounts of
mVIM, such as T11 and T19, whereas the corresponding
urine samples had none. One explanation could be that
the rate of apoptosis of these particular tumors was limited;
thus, the quantity of apoptotic-derived tumor DNA was not
sufficient to be detected in patients’ urine. Alternatively,
plasma DNA could be used for the detection of mVIM.
Interestingly, a previous study36 suggested that the con-
centration of mutated K-ras DNA in plasma is similar to that
in urine of patients with CRC. Urine can be collected in a
larger volume with less contamination; thus, more DNA
could be used, which would result in a higher frequency of
detection of mutated K-ras DNA from patients with mutated
K-ras CRC. Thus, we do not think that using plasma DNA
would increase the detection of circulatingmVIM in patients
with CRC compared with using LMW urine DNA.
In summary, the detection of circulation-derived, hy-
permethylated CRC-associated DNA markers in the urine
of patients with CRC provides a promising approach for
developing a urine test for CRC screening that includes
methylatedDNAmarkers. A larger sample size to determine
the performance of mVIM alone as a urine marker or com-
bined with other CRC genetic markers in urine to detect
CRC or adenoma is the next step toward the development
of a urine screening test for the early detection of CRC. The
success of this study could deliver a urine-based screening
test for colon cancer and, ultimately, for other cancers withknown genetic and epigenetic alterations that could be
used for screening, detecting the tumor early, monitoring
recurrence, and managing the disease.
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